Nimesulide as a Potential Treatment for Primary Effusion Lymphoma
Author Information
Author(s): George Paul Arun Sharma-Walia, Neelam Chandran, B. C. Chandran
Primary Institution: H. M. Bligh Cancer Research Laboratories, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, United States of America
Hypothesis
Understanding the role of COX-2 in PEL might lead to identifying new drug targets for treatment.
Conclusion
Nimesulide shows promise as a chemotherapeutic agent against primary effusion lymphoma by inducing cell death and disrupting viral latency.
Supporting Evidence
- Nimesulide induced sustained cell death and G1 arrest in BCBL-1 cells.
- Nimesulide reduced KSHV latent gene expression and disrupted p53-LANA-1 protein complexes.
- Nimesulide down-regulated cell survival kinases and angiogenic factors.
- Nimesulide treatment blocked KSHV latency genes and induced apoptosis.
Takeaway
Nimesulide, a common pain reliever, might help treat a type of cancer linked to a virus by stopping the cancer cells from growing.
Methodology
The study used various human lymphoma cell lines to assess the effects of nimesulide on cell proliferation, apoptosis, and gene expression.
Limitations
The study primarily used cell lines, which may not fully represent the complexity of human disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website